Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

← catalyst calendar

NCT05478304 · readout ≤ 1,960 d

Sponsored by AtriCure, Inc. (industry) · ATRC — their whole pipeline →. With Population Health Research Institute.

Phase

Not applicable

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

6,573actual

Sites

138

Countries

Australia, Austria, Belgium +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-01-25

actual

When the study began enrolling

Primary completion

Dec 2031

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Apr 2032

estimated

The whole study's end, after follow-up

First posted

2022-07-28

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-24

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Ischemic Stroke
Systemic Embolism

Intervention

Device: AtriClip LAA Exclusion System

Primary outcomes

what the primary-completion date above is the date OF

Primary Effectiveness Endpoint

measured Common termination point (median follow-up for 5 years)

Primary Safety Endpoint

measured 30 days post index procedure

Publications

PMID 39395566 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ATRC's whole pipeline · Catalyst calendar · Every registered study · What changed